Treatment patterns and costs of care for patients with relapsed and refractory Hodgkin lymphoma treated with brentuximab vedotin in the United States: A retrospective cohort study

OBJECTIVES: Although brentuximab vedotin (BV) has changed the management of patients with relapsed or refractory Hodgkin lymphoma (RRHL), little information is available on routine clinical practice. We identified treatment patterns and costs of care among RRHL patients in the United States (US) tre...

Descripción completa

Detalles Bibliográficos
Autores principales: Szabo, Shelagh M., Hirji, Ishan, Johnston, Karissa M., Juarez-Garcia, Ariadna, Connors, Joseph M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5633181/
https://www.ncbi.nlm.nih.gov/pubmed/28991893
http://dx.doi.org/10.1371/journal.pone.0180261

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5633181/
https://www.ncbi.nlm.nih.gov/pubmed/28991893
http://dx.doi.org/10.1371/journal.pone.0180261

Ejemplares similares